Several biopharma and life sciences hedge funds suffered sharp losses in August after the shares of one of their top holdings tanked following bad news.
It’s business as usual for the volatile group, which is used to huge one day surges or collapses in their investments after a company makes a significant announcement related to a clinical trial or financial results.
Casdin
